Idera holds out hope for IMO-2055 after negative Phase II head and neck cancer data
This article was originally published in Scrip
Executive Summary
Undeterred by topline results from a Phase II clinical trial which did not meet the primary endpoint Idera Pharmaceuticals still believes it can find ways to make its oncology drug candidate IMO-2055 work. When given in combination with ImClone's Erbitux (cetuximab) to treat recurrent or metastatic squamous cell carcinoma of the head and neck, progression-free survival did not improve.